Real-world evidence of brigatinib as second-line treatment after crizotinib for ALK+ non-small cell lung cancer using South Korean claims data (K-AREAL).
Jeong Eun LeeJin Hyun NamSun Hong KwonBo Kyung KimSeung Min HaPublished in: Cancer medicine (2024)
In this first nationwide retrospective study using national insurance claim data, brigatinib demonstrated real-world clinical benefit as second-line treatment after prior crizotinib in ALK+ NSCLC patients in South Korea.
Keyphrases
- advanced non small cell lung cancer
- end stage renal disease
- small cell lung cancer
- electronic health record
- chronic kidney disease
- health insurance
- cross sectional
- ejection fraction
- big data
- quality improvement
- prognostic factors
- peritoneal dialysis
- epidermal growth factor receptor
- data analysis
- deep learning
- replacement therapy
- artificial intelligence